Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Vizsgálat
Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer
2027. júl. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial
2026. dec. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publikáció
CDK4 maintains cytoskeletal homeostasis by restraining actomyosin contractility.
2026. nov. 4.· EMBO reports· PUBMED
Vizsgálat
Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast Cancer
2026. nov. 1.· PHASE3 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis
2026. nov. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publikáció
[CDK4/6 inhibitor to antibody-drug conjugates in HER2-low metastatic breast cancer: sequential therapeutic management of a case report.].
2026. nov. 1.· Recenti progressi in medicina· PUBMED
Publikáció
Novel therapies create potential new options for patients with advanced breast cancer: First-line sacituzumab govitecan plus pembrolizumab may improve long-term outcomes for patients with advanced triple-negative breast cancer, whereas the new CDK4/6 inhibitor fovinaciclib shows promising efficacy.
2026. nov. 1.· Cancer· PUBMED
Publikáció
Study design of the phase III ADELA trial of elacestrant with or without everolimus in ESR1-mutated ER+/HER2- advanced breast cancer after progression on endocrine therapy plus a CDK4/6 inhibitor.
2026. okt. 31.· Future oncology (London, England)· PUBMED
Vizsgálat
Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing
2026. okt. 30.· PHASE3 · NOT_YET_RECRUITING· CTGOV
Publikáció
CDK4/6 Inhibitors and Curcumin Synergistically Suppress HER2- Breast Cancer via Lethal ROS and Inhibition of Metastasis.
2026. okt. 18.· Cancer science· PUBMED
Publikáció
PLK1 inhibition by onvansertib enhances paclitaxel efficacy and overcomes resistance in HR+/HER2- breast cancer refractory to endocrine therapy and CDK4/6 inhibitors.
2026. okt. 8.· Molecular cancer therapeutics· PUBMED
Publikáció
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-induced hepatotoxicity and its resolution: a study of seven cases.
2026. okt. 8.· Histopathology· PUBMED
Publikáció
Lactate Dehydrogenase-to-Albumin Ratio and Glasgow Prognostic Score as Prognostic Markers in Metastatic Breast Cancer Treated with CDK4/6 Inhibitors.
2026. szept. 29.· Current oncology (Toronto, Ont.)· PUBMED
Publikáció
Healthcare Cost Patterns in CDK4/6 Inhibitor-Treated HR+/HER2- Metastatic Breast Cancer.
2026. szept. 28.· Clinical drug investigation· PUBMED
Publikáció
Identification of a Conserved Temporal Molecular Response Signature to CDK4/6 Inhibition Through Multi-Omics Integration Across Cancer Cell Lines.
2026. szept. 24.· International journal of molecular sciences· PUBMED
Publikáció
Crossing the toxicity threshold: a repeated landmark analysis of early toxicities and treatment modification during first-line CDK4/6 inhibitor therapy.
2026. szept. 24.· Cancer chemotherapy and pharmacology· PUBMED
Publikáció
Prognostic value of hormone receptor expression in patients with HR+/HER2- advanced BC treated with first-line ET+CDK4/6i: results from the multicentre observational, real-world PALMARES-2 study.
2026. szept. 22.· EClinicalMedicine· PUBMED
Publikáció
Integrative Systems Biology Prioritizes BCL2, ALK, and CDK4 as Therapeutic Candidates in Neuroblastoma through Multi-Centrality Network Analysis, Cross-Database Validation, Independent Docking Validation, and Confidence-Threshold Sensitivity Analysis.
2026. szept. 21.· Computational biology and chemistry· PUBMED
Publikáció
Prognostic Value of Baseline Metabolic Tumor Volume on [18F]FDG PET/CT in Metastatic Breast Cancer Treated With CDK4/6 Inhibitors.
2026. szept. 20.· Clinical breast cancer· PUBMED
Publikáció
Safety-guided selection of CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer: toxicity profiles, dose modification, and clinical risk-benefit considerations.
2026. szept. 16.· Therapeutic advances in drug safety· PUBMED
Publikáció
Integration of MRI radiomics with immune profiling to predict response to CDK6 inhibitors in high-grade glioma.
2026. szept. 15.· Frontiers in immunology· PUBMED
Publikáció
CDK4/6 Inhibitor Abemaciclib Arrests and Reverses Kidney Cyst Progression in Preclinical Models of Autosomal Dominant Polycystic Kidney Disease.
2026. szept. 14.· Journal of the American Society of Nephrology : JASN· PUBMED
Publikáció
First-line CDK4/6 inhibitor treatment of HR-positive, HER2-negative metastatic breast cancer: real-world data from Ho Chi Minh City Oncology Hospital, Vietnam.
2026. szept. 7.· Frontiers in oncology· PUBMED
Publikáció
On-Treatment NLR Dynamics During CDK4/6 Inhibition Are Associated with Overall Survival in Metastatic Breast Cancer.
2026. szept. 7.· Cancers· PUBMED
Publikáció
CRC cell cycle arrest and early apoptosis induction by mononuclear octahedral cobalt(III) Schiff base through the inhibition of CDK4/6 and BCL2.
2026. szept. 5.· Medical oncology (Northwood, London, England)· PUBMED
Publikáció
Editor's Note: miR-6883 Family miRNAs Target CDK4/6 to Induce G1 Phase Cell-Cycle Arrest in Colon Cancer Cells.
2026. szept. 2.· Cancer research· PUBMED
Vizsgálat
Reduction of treatment after Complete Response in Advanced Hormone-Sensitive Breast Cancer
2026. szept. 1.· PHASE3 · NOT_YET_RECRUITING· CTIS
Vizsgálat
Culmerciclib Combined With Letrozole and Dual HER2 Blockade as Neoadjuvant Therapy for HR+/HER2+ Breast Cancer
2026. szept. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publikáció
Downregulation of circ_0001112 Enhances Myocardial Infarction Through Regulation of miR-324-5p/CDK6 Axis.
2026. szept. 1.· Journal of biochemical and molecular toxicology· PUBMED
Publikáció
CDK4/6 Inhibitors in the Management of Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Advanced Breast Cancer in Indonesia: Challenges, Opportunities, and Recommendations.
2026. szept. 1.· Asia-Pacific journal of clinical oncology· PUBMED